The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma

European Journal of Haematology

Volumn 84, Issue 3, 2010, Pages 266-270

  Garcia Sanz R ^a   Gonzalez Lopez T J ^a   Vazquez L ^a   Hermida, G ^b   Graciani, I F ^a   San Miguel, J F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

Author keywords

Cyclophosphamide; Dexamethasone; Hodgkin's lymphoma; Refractory disease; Thalidomide; Transplantation

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IBRITUMOMAB TIUXETAN; MELPHALAN; OXALIPLATIN; PACLITAXEL; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; THALIDOMIDE; TOPOTECAN; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; HODGKIN DISEASE; HUMAN; LIMB PAIN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PARESTHESIA; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARMUSTINE; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEOXYCYTIDINE; DEXAMETHASONE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; MELPHALAN; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISOLONE; PREDNISONE; PROCARBAZINE; REMISSION INDUCTION; SALVAGE THERAPY; THALIDOMIDE; TOPOTECAN; TRANSPLANTATION, AUTOLOGOUS; VIDARABINE; VINBLASTINE; VINCRISTINE;

EID: 76249088899     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01375.x     Document Type: Article

References (15)

1. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008 141 : 3 13
2. Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology Am Soc Hematol Educ Program 2008 326 333.
3. Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma 2008 49 : 1238 1245.
4. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004 22 : 2835 2841.
5. Morgenfeld MC, Pavlovsky A, Suarez A, Somoza N, Pavlovsky S, Palau M, Barros CA. Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. Cancer 1975 36 : 1241 1249.
6. Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997 20 : 451 458.
7. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008 112 : 831 836.
8. Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol 1998 16 : 584 588.
9. Zojer N, Mirzaei S, Ludwig H. Successful treatment of a patient with lymphocyte-predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetan. Eur J Haematol 2008 81 : 322 324.
10. Younes A, Preti HA, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA, Samuels BI, Palmer JL, Cabanillas F. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2001 12 : 923 927.
11. Bordonaro R, Ferrau F, Giuffrida D, Cali S, Priolo D, Colina P, Ursino M, Failla G. Fludarabine phosphate as an active and well tolerated salvage therapy in an elderly heavily pretreated Hodgkin's disease patient: a case report. Tumori 1999 85 : 288 289.
12. El GT, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007 18 : 1363 1368.
13. Pro B, Younes A, Albitar M, et al. Thalidomide for patients with recurrent lymphoma. Cancer 2004 100 : 1186 1189.
14. Garcia-Sanz R. Thalidomide in multiple myeloma. Expert Opin Pharmacother 2006 7 : 195 213.
15. Kuruvilla J, Song K, Mollee P, Panzarella T, McCrae J, Nagy T, Crump M, Keating A. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology 2006 11 : 25 9.